Ally Bridge Group
Latest statistics and disclosures from Ally Bridge Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SLNO, PRAX, NERV, OVID, CMPS, and represent 37.13% of Ally Bridge Group's stock portfolio.
- Added to shares of these 10 stocks: SLNO (+$7.8M), TARS (+$5.7M), CMPX (+$5.3M), CTMX, PRAX, CATX, ALMS, URGN, CAPR, MAZE.
- Started 12 new stock positions in URGN, RLMD, CAPR, MAZE, ALMS, KPTI, TARS, ANTX, IKT, CMPX. CATX, CTMX.
- Reduced shares in these 7 stocks: EWTX (-$8.9M), REPL (-$7.3M), Atai Life Sciences Nv (-$7.0M), TSHA (-$5.3M), IVA, ABVX, CMPS.
- Sold out of its positions in TSHA, Atai Life Sciences Nv.
- Ally Bridge Group was a net buyer of stock by $25M.
- Ally Bridge Group has $124M in assets under management (AUM), dropping by 28.99%.
- Central Index Key (CIK): 0001822947
Tip: Access up to 7 years of quarterly data
Positions held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ally Bridge Group
Ally Bridge Group holds 26 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Soleno Therapeutics (SLNO) | 10.8 | $13M | +138% | 400k | 33.48 |
|
| Praxis Precision Medicines I Com New (PRAX) | 8.5 | $11M | +65% | 33k | 322.19 |
|
| Minerva Neurosciences Com New (NERV) | 8.1 | $10M | 1.7M | 6.03 |
|
|
| Ovid Therapeutics (OVID) | 5.1 | $6.3M | +57% | 2.8M | 2.22 |
|
| Compass Pathways Sponsored Ads (CMPS) | 4.7 | $5.8M | -5% | 1.0M | 5.53 |
|
| Tarsus Pharmaceuticals (TARS) | 4.6 | $5.7M | NEW | 81k | 70.15 |
|
| Solid Biosciences Com New (SLDB) | 4.5 | $5.5M | +85% | 767k | 7.20 |
|
| Compass Therapeutics Call Option (CMPX) | 4.3 | $5.3M | NEW | 1.0M | 5.29 |
|
| Promis Neurosciences Com Shs (PMN) | 4.2 | $5.3M | +66% | 414k | 12.70 |
|
| Edgewise Therapeutics (EWTX) | 4.1 | $5.1M | -63% | 161k | 31.50 |
|
| Uniqure Nv SHS Call Option (QURE) | 4.0 | $4.9M | +50% | 300k | 16.35 |
|
| Eupraxia Pharmaceuticals (EPRX) | 3.9 | $4.8M | +65% | 660k | 7.24 |
|
| Cytomx Therapeutics (CTMX) | 3.4 | $4.2M | NEW | 900k | 4.70 |
|
| Inventiva Sa Ads (IVA) | 3.3 | $4.1M | -50% | 745k | 5.55 |
|
| Perspective Therapeutics Com New (CATX) | 3.1 | $3.9M | NEW | 927k | 4.17 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.0 | $3.8M | -51% | 34k | 111.35 |
|
| Alumis (ALMS) | 3.0 | $3.7M | NEW | 167k | 22.03 |
|
| Urogen Pharma (URGN) | 2.9 | $3.6M | NEW | 202k | 17.98 |
|
| Capricor Therapeutics Com New (CAPR) | 2.8 | $3.5M | NEW | 114k | 30.40 |
|
| Maze Therapeatics Call Option (MAZE) | 2.4 | $3.0M | NEW | 100k | 29.85 |
|
| Aadi Bioscience (WHWK) | 2.3 | $2.8M | 818k | 3.45 |
|
|
| Inhibikase Therapeutics Com New (IKT) | 1.8 | $2.2M | NEW | 1.3M | 1.68 |
|
| Replimune Group Call Option (REPL) | 1.5 | $1.9M | -79% | 247k | 7.65 |
|
| An2 Therapeutics (ANTX) | 1.5 | $1.8M | NEW | 526k | 3.42 |
|
| Relmada Therapeutics (RLMD) | 1.2 | $1.5M | NEW | 211k | 6.96 |
|
| Karyopharm Therapeutics Com New Call Option (KPTI) | 1.1 | $1.4M | NEW | 250k | 5.57 |
|
Past Filings by Ally Bridge Group
SEC 13F filings are viewable for Ally Bridge Group going back to 2020
- Ally Bridge Group 2026 Q1 filed May 18, 2026
- Ally Bridge Group 2025 Q4 filed Feb. 17, 2026
- Ally Bridge Group 2025 Q3 filed Nov. 14, 2025
- Ally Bridge Group 2025 Q2 filed Aug. 14, 2025
- Ally Bridge Group 2025 Q1 filed May 15, 2025
- Ally Bridge Group 2024 Q4 filed Feb. 14, 2025
- Ally Bridge Group 2024 Q3 filed Nov. 14, 2024
- Ally Bridge Group 2024 Q2 filed Aug. 14, 2024
- Ally Bridge Group 2024 Q1 filed May 15, 2024
- Ally Bridge Group 2023 Q4 filed Feb. 14, 2024
- Ally Bridge Group 2023 Q3 filed Nov. 14, 2023
- Ally Bridge Group 2023 Q2 filed Aug. 14, 2023
- Ally Bridge Group 2023 Q1 filed May 15, 2023
- Ally Bridge Group 2022 Q4 filed Feb. 14, 2023
- Ally Bridge Group 2022 Q3 filed Nov. 14, 2022
- Ally Bridge Group 2022 Q2 filed Aug. 15, 2022